Synaptive acquired by consortium in restructuring

TORONTO – Synaptive Medical, a global medical technology innovator, has announced the successful completion of a strategic restructuring and the closing of a significant new private investment. This milestone marks a pivotal new chapter for the company – one that strengthens its mission to revolutionize neurosurgical care in close collaboration with clinicians worldwide.

According to a press release, the company has been wholly acquired by a mission-aligned consortium of MedTech executives, clinicians, and experienced investors who bring deep domain expertise and a shared vision for the future of neurosurgical care.

“We remain deeply committed to investing in the people, tools, and technologies that drive progress in surgical planning, neuro-navigation, robotic exoscopy, and advanced MRI,” said Cameron Piron (pictured), president and founder of Synaptive Medical. “From enhancing surgical precision with our integrated robotic and navigation systems to expanding the diagnostic potential of our MRI platforms, Synaptive is redefining the future of surgery—from imaging to intervention.”

Earlier this year, Synaptive obtained protection under the Companies’ Creditors Arrangement Act (CCAA). The company reported secured debt totalling approximately US$104 million, including around $54.8 million owed to senior secured creditor Export Development Canada (EDC).

The company has faced significant financial difficulties, driven by high R&D costs, maintenance of its intellectual property portfolio, and expenses related to its sizable workforce. Sales revenue failed to keep pace with expenses, and the situation was further exacerbated by market uncertainties related to potential US tariffs, impacting the company’s largest market.

As part of its transformation, Synaptive is reaffirming its commitment to its comprehensive product portfolio. The company will continue to expand its integrated surgical suite – including Modus X™, Modus Nav™, and Modus Plan™ – alongside its dedicated MRI platform.

These advancements are closely aligned with long-standing partnerships at leading hospitals and clinical institutions around the world.

Throughout the restructuring, Synaptive maintained uninterrupted customer support while continuing to execute on its innovation roadmap. Recent milestones include major software upgrades across its platforms and the launch of new collaborations with internationally recognized medical centers in the United States and Europe.

The newly secured investment will bring the company to profitability and reflects strong confidence in Synaptive’s strategic direction and long-term growth.

“This investment represents a powerful recommitment to Synaptive’s mission: to transform brain health in the 21st century for patients and families in need,” said Dr. Joshua Bernstock, neurosurgeon and incoming board member.

“We’re proud to join forces with a team that is not only passionate about elevating the standard of care but also fearless in pushing the boundaries of what’s possible in diagnostics and surgical innovation.”

This investment represents the first phase of a broader capital initiative, with additional funding expected in the coming weeks to further support Synaptive’s growth strategy and accelerate its innovation pipeline.

About Synaptive Medical
Synaptive Medical Inc. is a Toronto-based global medical technology company dedicated to solving complex challenges in surgery, imaging, and data integration to improve patient outcomes. Its integrated suite of solutions—spanning MRI, surgical planning, navigation, and robotic visualization—delivers intelligent, patient-centric technology that enhances clinical decision-making and efficiency across every stage of neurosurgical care.